The presence of cytogenetic abnormality and the absence of variants in DNMT3A, TET2, or ASXL1 genes were associated with a higher likelihood of progressing to t-MN and an inferior survival. The gene discussed is TET2; the disease is therapy-related myeloid neoplasm.